研究スタッフ

[Published] 2020/3/11 [Last updated] 2023/8/2

Kazuki Sudo

Head of Physicians

Dr. Kazuki Sudo is a medical oncologist specialized in gynecologic cancer, breast cancer and rare cancers. He is serving as an attending physician at the Department of Experimental Therapeutics, Breast and Medical oncology, and Rare Cancer Center.

Kazuki Sudoの代表的な論文

  1. Iwasa S, Koyama T, Nishino M, Kondo S, Sudo K, Yonemori K, Yoshida T, Tamura K, Shimizu T, Fujiwara Y, Kitano S, Shimomura A, Sato J, Yokoyama F, Iida H, Kondo M, Yamamoto N. First-in-human study of ONO-4578, an antagonist of prostaglandin E2 receptor 4, alone and with nivolumab in solid tumors. Cancer Sci. 2023 Jan;114(1):211-220.
  2. Abe S, Matsuzaki J, Sudo K, Oda I, Katai H, Kato K, et al. A novel combination of serum microRNAs for the detection of early gastric cancer. Gastric Cancer. 2021;24(4):835-43.
  3. Sudo K, Kato K, Matsuzaki J, Takizawa S, Aoki Y, Shoji H, et al. Identification of serum microRNAs predicting the response of esophageal squamous-cell carcinoma to nivolumab. Japanese Journal of Clinical Oncology. 2020;50(2):114-21.
  4. Sudo K, Kato K, Matsuzaki J, Boku N, Abe S, Saito Y, et al. Development and Validation of an Esophageal Squamous Cell Carcinoma Detection Model by Large-Scale MicroRNA Profiling. JAMA network open. 2019;2(5):e194573-e.
  5. Hirakawa A, Sudo K, Yonemori K, Sadachi R, Kinoshita F, Kobayashi Y, et al. A comparative study of longitudinal toxicities of cytotoxic drugs, molecularly targeted agents, immunomodulatory drugs, and cancer vaccines. Clinical Pharmacology & Therapeutics. 2019.
  6. Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. Journal of Clinical Oncology. 2014;32(30):3400.
  7. Song S, Ajani JA, Honjo S, Maru DM, Chen Q, Scott AW, et al. Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer research. 2014;74(15):4170-82.
  8. Ajani JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, et al. ALDH‐1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Molecular oncology. 2014;8(1):142-9.
  9. Sudo K, Taketa T, Correa AM, Campagna M-C, Wadhwa R, Blum MA, et al. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. Journal of clinical oncology. 2013;31(34):4306.
  10. Cheedella N, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T,,,Sudo K, et al. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Annals of Oncology. 2012;24(5):1262-6.
MEMBERS LIST